Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 6,000 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $22.53, for a total transaction of $135,180.00. Following the transaction, the vice president now owns 8,112 shares in the company, valued at approximately $182,763.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Brent Johnson also recently made the following trade(s):

  • On Wednesday, December 11th, Brent Johnson sold 4,300 shares of Iradimed stock. The stock was sold at an average price of $23.00, for a total transaction of $98,900.00.
  • On Monday, December 2nd, Brent Johnson sold 9,800 shares of Iradimed stock. The stock was sold at an average price of $21.96, for a total transaction of $215,208.00.
  • On Friday, November 29th, Brent Johnson sold 10,000 shares of Iradimed stock. The stock was sold at an average price of $22.09, for a total transaction of $220,900.00.
  • On Wednesday, November 27th, Brent Johnson sold 10,000 shares of Iradimed stock. The stock was sold at an average price of $21.96, for a total transaction of $219,600.00.
  • On Monday, November 25th, Brent Johnson sold 6,000 shares of Iradimed stock. The stock was sold at an average price of $22.80, for a total transaction of $136,800.00.
  • On Friday, November 22nd, Brent Johnson sold 6,000 shares of Iradimed stock. The stock was sold at an average price of $23.25, for a total transaction of $139,500.00.
  • On Wednesday, November 20th, Brent Johnson sold 6,000 shares of Iradimed stock. The stock was sold at an average price of $23.42, for a total transaction of $140,520.00.
  • On Monday, November 18th, Brent Johnson sold 6,000 shares of Iradimed stock. The stock was sold at an average price of $22.86, for a total transaction of $137,160.00.
  • On Friday, November 15th, Brent Johnson sold 6,000 shares of Iradimed stock. The stock was sold at an average price of $23.02, for a total transaction of $138,120.00.
  • On Wednesday, November 13th, Brent Johnson sold 6,000 shares of Iradimed stock. The stock was sold at an average price of $23.68, for a total transaction of $142,080.00.

Iradimed stock traded down $1.05 during trading hours on Friday, reaching $24.71. 4,284 shares of the company’s stock traded hands, compared to its average volume of 60,072. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.05 and a current ratio of 9.82. Iradimed Corp has a fifty-two week low of $16.68 and a fifty-two week high of $29.80. The firm has a market capitalization of $274.60 million, a price-to-earnings ratio of 57.47 and a beta of 1.48. The firm’s 50 day moving average is $23.26 and its 200-day moving average is $21.34.

Iradimed (NASDAQ:IRMD) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.07. Iradimed had a net margin of 22.51% and a return on equity of 16.24%. The company had revenue of $9.96 million for the quarter, compared to the consensus estimate of $9.85 million. Analysts predict that Iradimed Corp will post 0.7 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its position in Iradimed by 109.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,024 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 1,057 shares during the period. HM Payson & Co. acquired a new position in Iradimed during the 2nd quarter valued at about $89,000. Barclays PLC lifted its position in Iradimed by 88.3% during the 3rd quarter. Barclays PLC now owns 5,352 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 2,509 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Iradimed by 34.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 10,500 shares of the medical equipment provider’s stock valued at $215,000 after purchasing an additional 2,666 shares during the period. Finally, Marshall Wace LLP acquired a new position in Iradimed during the 1st quarter valued at about $241,000. Institutional investors own 26.40% of the company’s stock.

Several research analysts recently issued reports on IRMD shares. BidaskClub upgraded shares of Iradimed from a “sell” rating to a “hold” rating in a research report on Friday. Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Saturday, October 26th. Finally, ValuEngine upgraded shares of Iradimed from a “hold” rating to a “buy” rating in a research report on Thursday.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Read More: Limitations to arbitrage trading

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.